YBGJ (Yubo International Biotech) EBITDA Margin %: 0.00% (As of Mar. 2026)


What is Yubo International Biotech EBITDA Margin %?

Yubo International Biotech YBGJ +30.43% EBITDA Margin % is 0.00% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Yubo International Biotech ranks worse than 98.04% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Yubo International Biotech's EBITDA for the three months ended in Mar. 2026 was $-0.26 Mil. Yubo International Biotech's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Yubo International Biotech's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.


Yubo International Biotech  (OTCPK:YBGJ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Yubo International Biotech EBITDA Margin % Related Terms


Yubo International Biotech EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Yubo International Biotech's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yubo International Biotech EBITDA Margin % Chart

Yubo International Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial -122.27 -1,132.69 -166.12 -52,900.00 -8,416.67

Yubo International Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -2,008.33 0.00

YBGJ vs ECIA, GCTK, RSCF: EBITDA Margin % Comparison

For the Medical Instruments & Supplies subindustry, Yubo International Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yubo International Biotech EBITDA Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Yubo International Biotech's EBITDA Margin % falls into.



Yubo International Biotech EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Yubo International Biotech's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1.01/0.012
=-8,416.67 %

Yubo International Biotech's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.26/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Yubo International Biotech (YBGJ) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Yubo International Biotech and its competitors. According to the industry distribution chart, Yubo International Biotech ranks #800 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 98%.
Is Yubo International Biotech's EBITDA Margin % too high?
Yubo International Biotech's current EBITDA Margin % is 0.00%. Based on the distribution chart, Yubo International Biotech ranks #800 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Yubo International Biotech's EBITDA Margin % compare to ECIA and GCTK?
According to the Medical Devices & Instruments industry distribution chart, Yubo International Biotech ranks #800 out of 816 companies for EBITDA Margin %. This places Yubo International Biotech in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Yubo International Biotech and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yubo International Biotech's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yubo International Biotech stock overvalued right now?
Yubo International Biotech (YBGJ) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Yubo International Biotech (YBGJ), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yubo International Biotech Business Description

Address No. 10 Chaoyang Park South Road, Room 1102, 11th Floor, Building 2, Chaoyang District, Beijing, CHN, 100026
Yubo International Biotech Ltd is a technology company focused on the research, development, and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.